N/A N=197 Iron Depletion and Replacement in Blood Donors
Anemia
Primary: Number of Participants With Adherence to Iron Replacement Therapy at Subsequent Donation — 116; 17 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=170 Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution
Blood Donors
Primary: Red Blood Cell Post-filtration Recovery — 92.57; 92.70; 90.96; 90.23 % recovery at day 0
Phase 1 N=5 Transfusion of Biotinylated Red Blood Cells
Anemia
Primary: Number of Participants That Had bRBC Detectable at 70 Days Post-intervention — 5 participants
N/A N=223 Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study
Iron-deficiency Anemia · Iron-deficiency
Primary: Haemoglobin Level — 11.35; 12.28 g/dL — p=0.025
N/A N=50 Sucrosom5al Iron Supplementation in Blood Donors
Iron-deficiency
Primary: Hb (g/dl) at E2 — 13.07 g/dl — p=0.031
N/A N=22 Survival and Recovery of Radio-labeled Platelets Derived From Mirasol-treated Whole Blood
Blood Safety
Primary: Platelet 24-hour Relative Recovery — 43.31; 52.01 Percentage of platelet count
Phase 3 N=110 Tdap Vaccine Safety for Plasma Donors
Tetanus
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 71; 42; 0 participants
N/A N=351 Evaluation of Physiological Variables and Detection of Blood Loss Using the Zynex Fluid Monitoring System, Model CM-1600
Fluid Loss
Primary: Change in the Relative Index (RI) After Minor Blood Loss (e.g., 500mL) — 2.9 Percent change in RI
N/A N=144 Community-Based Communication Approaches for Blood Donation in Ghana
Blood Donors
Primary: Donation Attempt — 2; 2; 2; 7 Participants — p=0.23
Phase 3 N=24,111 Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay
Healthy Donors · HIV Positive
Primary: PRISM HIV O Plus Test Data for Specificity — 10; 15589 participants
N/A N=131 Noninvasive Hemoglobin Testing, Prospective Blood Donors
Healthy · Anemia
Primary: Rad-67 Sensitivity — 44 percentage of sensitivity
Phase 3 N=55 Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.
Meningitis, Meningococcal, Serogroup B
Primary: Number of Subjects Reporting Unsolicited Adverse Events (AEs). — 0; 0; 0; 0 Subjects
Early Phase 1 N=5 RHD Genotype Matched Red Cells for Anti-D
Sickle Cell Disease · Anti-D Antibodies
Primary: Anti-D Recurrence — 0; 5 Participants
N/A N=70 Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors
Leukapheresis
Primary: Mononuclear Cell Collection Efficiency — 61; 57 % of processed MNCs that were collected
Phase 2 N=43 Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis (Aim 3)
Cardiovascular Diseases
Primary: Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at Baseline — 4.87…
N/A N=54 RhD+ Blood Transfusion to Asian-type DEL Recipients
Blood Transfusion · Rhesus Isoimmunisation Due to Anti-D · Blood Group Antigen Abnormality
Primary: Occurrence of Alloanti-D Immunization in Asian-type DEL Recipients Transfused With RhD+ RBCs — 42; 12 Participants — p=< 0.001
N/A N=79 Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality
Iron Deficiency
Primary: 51-Chromium 24-hour Post-transfusion RBC Recovery of Units — 1.6; -0.4 percentage change
N/A N=120 Evaluation of Physiological Variables and Detection of Blood Loss in Healthy Adults With Different Subject Positioning by the CM-1500
Fluid Loss · Blood Loss
Primary: Impact of Subject Positioning on Percent Change of Heart Rate (HR) After Minor Blood Loss (e.g., 500mL) — 10.7; 14.7 percent change
N/A N=77 Clinical Evaluation of the CM-1500 During Apheresis Blood Donation
Fluid Loss
Primary: Characterize Changes in the Relative Index During an Apheresis Procedure — 94.9; 99.3 Relative Index
Phase 2 N=40 Preventing Stem Cell Transplant Complications With a Blood Separator Machine
MDS (Myelodysplastic Syndrome) · Myeloproliferative Disorder · Lymphoma, Non-Hodgkin
Primary: Overall Survival — 36 Participants
N/A N=26 Noninvasive Hemoglobin Repeatability and Reproducibility in a Blood Donation Setting
Healthy · Anemia
Primary: Coefficient of Variation of Rad-67 — 4.50 Coefficient of Variation percentage
Phase 2 N=38 Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors
Cytomegalovirus Infections
Primary: Cellular Immune Response in Vaccine Recipients — 14 participants
Phase 3 N=4,994 Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial
Transfusion · Age of Blood
Primary: Mortality at Day 90 — 610; 594; 264; 259 participants
N/A N=14 Fresh Versus Old Red Blood Cells for Transfusion
Iron, Abnormal Blood Level · Other Abnormal Blood Chemistry
Primary: Measure of Non-transferrin-bound Iron — 0.16; 3.17 μM
N/A N=45 A Clinical Study to Investigate if Transfusion of Patients Own Shed Blood Improves the Immunological Status in Comparison to Transfusion of Donor Blood ("Bank Blood")
Arthroplasty, Replacement, Knee · Blood Transfusion, Autologous · Blood Transfusion
Primary: Frequency of Natural Killer Cells as Measured With Flow Cytometry. — 2.98; 2.26 total number of cells * 10^5/mL
Phase 3 N=199 Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients
Hemorrhagic Shock · Acute Blood Loss Anemia · Traumatic Brain Injury
Primary: Packed Red Blood Cells Equivalents Units Transfused (1 Whole Blood Unit Treated as 1 Packed Red Blood Cell Unit and 1 Fresh Frozen Plasma Unit) — 3.8; 5.7 units
N/A N=254 Frozen Red Blood Cell Transfusions in Trauma Patients
Blood Loss · Anemia · Trauma
Primary: Tissue Oxygenation — 100.3; 98.2; 98.3 percentage of baseline
Phase 3 N=26 Age of Blood in Sickle Cell Transfusion
Sickle Cell Disease
Primary: Proportion of Biochemically Old Red Cell Units — 0.71; 0.86 proportion biologically old units — p=0.051
Early Phase 1 N=22 Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease
Sickle Cell Disease · Sickle Cell Anemia
Primary: Mean Red Blood Cells Lifespan in Participants — 64.1; 113.4; 126.0; 123.7 day — p=<0.001
Phase 4 N=154 Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors
Fatigue · Iron Deficiency
Primary: Level of Fatigue Before and After Iron Treatment/Placebo, Using a 10 Point Visual Analogue Scale. — 3.4; 3.5 centimeter — p=0.69